SCHEMBL2174994

SCHEMBL2174994

O=C1CC(Br)CC(=O)N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19047109 0.73 MAP3K14 (0.60)
SCHEMBL9256 0.71
SCHEMBL1359359 0.69
Ammonia Solution, Strong SCHEMBL23360905 0.69
SCHEMBL908288 0.69
SCHEMBL1079678 0.69
SCHEMBL10909993 0.69
SCHEMBL6042160 0.69
Bromide SCHEMBL1086848 0.67 CRBN (0.50)
Hydrochloric Acid SCHEMBL2278643 0.67 CRBN (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070155967-A1 Process for producing piperidine-2,6 diones heterocyclically substituted in the 3-position GRUENENTHAL GMBH (DE) 2007-07-05 US claimed
US-20250382285-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2025-12-18 US disclosed
US-20250368631-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2025-12-04 US disclosed
US-12421220-B2 Bicyclic-substituted glutarimide cereblon binders C4 THERAPEUTICS, INC. (US) 2025-09-23 US disclosed
US-20250122179-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2025-04-17 US disclosed
EP-4536656-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 Therapeutics, Inc. (US) 2025-04-16 EP disclosed
CN-119823124-A Compounds for targeted degradation of BRD9 C4医药公司 2025-04-15 CN disclosed
US-20250084081-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 C4 THERAPEUTICS, INC. (US) 2025-03-13 US disclosed
CN-115279370-B Compounds for targeted degradation of BRD9 C4医药公司 2025-01-10 CN disclosed
US-12157735-B2 Compounds for targeted degradation of BRD9 C4 THERAPEUTICS, INC. (US) 2024-12-03 US disclosed
US-20060211728-A1 Thalidomide analogs P2D INC. 2006-09-21 US disclosed
EP-1663223-A2 THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH &amp; HUMAN SERVICES (US) 2006-06-07 EP disclosed
US-20050192313-A1 Substituted thioacetamides CEPHALON, INC. (US) 2005-09-01 US disclosed
US-6919367-B2 Substituted thioacetamides CEPHALON, INC. (US) 2005-07-19 US disclosed
WO-2005028436-A2 THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2005-03-31 WO disclosed
EP-1438288-A1 SUBSTITUTED THIOACETAMIDES CEPHALON, INC. (US) 2004-07-21 EP disclosed
US-20040116445-A1 Substituted thioacetamides CEPHALON INC. 2004-06-17 US disclosed
US-6670358-B2 Substituted thioacetamides CEPHALON, INC. 2003-12-30 US disclosed
WO-2003037853-A1 SUBSTITUTED THIOACETAMIDES CEPHALON, INC. (US) 2003-05-08 WO disclosed
US-20020183334-A1 Substituted thioacetamides CEPHALON, INC. 2002-12-05 US disclosed